文献速递神经免疫

症状前多发性硬化患者的血清神经丝轻链水平

Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项美国军人嵌套病例对照研究显示,多发性硬化临床发病前约6年血清神经丝轻链(sNfL)已升高,且越接近发病差异越明显;发病时sNfL显著上升,提示MS存在持续数年的前驱期。

要点

  • MS临床发病前中位6年sNfL已高于匹配对照。
  • 越接近发病,sNfL与对照的差异越大。
  • 个体内sNfL升高≥5 pg/mL与MS风险升高相关。

核心结论

  • sNfL在MS临床发病前6年已升高,提示MS可能存在持续数年的前驱期且神经轴索损伤已发生。

研究设计与样本

  • 美国军人血清库嵌套病例对照研究,纳入60例MS患者并按年龄、性别、种族和采样日期匹配60例对照。

主要发现

  • 个体内sNfL升高≥5 pg/mL与MS风险升高相关(率比7.50,95%CI 1.72-32.80)。

临床怎么用

  • sNfL或可作为MS前驱期神经轴索损伤的生物标志物,辅助早期识别高危个体。

局限性

  • 样本量基于可用资金确定,可能限制统计效能。
  • 研究对象为美国军人,结果外推至一般人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Unrecognized demyelinating events often precede the clinical onset of multiple sclerosis (MS). Identification of these events at the time of occurrence would have implications for early diagnosis and the search of causal factors for the disease. OBJECTIVE: To assess whether serum neurofilament light chain (sNfL) levels are elevated before the clinical MS onset. DESIGN, SETTING, AND PARTICIPANTS: Nested case-control study among US military personnel who have serum samples stored in the US Department of Defense Serum Repository. Serum samples were collected from 2000 to 2011; sNfL assays and data analyses were performed from 2018 to 2019. We selected 60 case patients with MS who either had 2 samples collected before onset (mean follow-up, 6.3 years) or 1 sample collected before and 1 after onset (mean follow-up, 1.3 years), among 245 previously identified case patients. For each case, we randomly selected 1 of 2 previously identified control individuals matched by age, sex, race/ethnicity, and dates of sample collection. The sample size was chosen based on the available funding. EXPOSURES: Serum NfL concentrations measured using an ultrasensitive single-molecule array assay (Simoa). MAIN OUTCOMES AND MEASUREMENTS: Log-transformed sNfL concentrations in case patients and control individuals compared using conditional logistic regression and linear mixed models. RESULTS: Mean age at baseline was 27.5 years, and 92 of 120 participants (76.7%) were men. Serum NfL levels were higher in case patients with MS compared with their matched control individuals in samples drawn a median of 6 years (range, 4-10 years) before the clinical onset (median, 16.7 pg/mL; interquartile range [IQR], 12.6-23.1 pg/mL vs 15.2 pg/m; IQR, 10.3-19.9 pg/mL; P = .04). This difference increased with decreasing time to the case clinical onset (estimated coefficient for interaction with time = 0.063; P = .008). A within-person increase in presymptomatic sNfL levels was associated with higher MS risk (rate ratio for ≥5 pg/mL increase, 7.50; 95% CI, 1.72-32.80). The clinical onset was associated with a marked increase in sNfL levels (median, 25.0; IQR, 17.1-41.3 vs 45.1; IQR, 27.0-102.7 pg/mL for presymptomatic and postonset MS samples; P = .009). CONCLUSIONS AND RELEVANCE: The levels of sNfL were increased 6 years before the clinical MS onset, indicating that MS may have a prodromal phase lasting several years and that neuroaxonal damage occurs already during this phase.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bjornevik K, Munger KL, Cortese M, et al. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 2020. PMID: 31515562. doi:10.1001/jamaneurol.2019.3238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。